Search

Displaying results 5181 - 5190 of 10000 in total
  1. Drug

    Xamoterol

    go.drugbank.com/drugs/DB13781
    Approved

    Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients. … It modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.

  2. Drug

    OT-551

    go.drugbank.com/drugs/DB05650
    Investigational

    OT-551 is a novel small molecule that is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the back of the eye. … It is intended to treat Age-related macular Degeneration (AMD), and preclinical research results indicate additional uses for OT-551, including treatment of early stage and advanced dry age-related macular

  3. Drug

    TM5614

    go.drugbank.com/drugs/DB16516
    Investigational

    An animal study in mice fed a fast-food diet with TM5614 treatment showed improved metabolic measurements and reduced liver steatosis[L31673,L31678]. … Further investigation of this compound is underway, including an exploratry Phase II study for its efficacy and safety for high-risk hospitalized patients with severe COVID-19 pneumonia[L31688].

  4. Drug

    Butriptyline

    go.drugbank.com/drugs/DB09016
    ApprovedWithdrawn

    Butriptyline is a tricyclic antidepressant which has been used in Europe since 1974. It is the isobutyl side chain homologue of amitriptyline.

  5. Drug

    MLN8054

    go.drugbank.com/drugs/DB13061
    Investigational

    MLN8054 has been used in trials studying the treatment of Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies.

  6. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230. … Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.

  7. Drug

    Tetrahydrofolic acid

    go.drugbank.com/drugs/DB00116
    InvestigationalNutraceutical

    It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids. … Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase.

  8. Drug

    AI-128

    go.drugbank.com/drugs/DB05841
    Experimental

    AI-128 is the first human demonstration of sustained release drug administration in the lung. … AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug.

  9. Drug

    Iproclozide

    go.drugbank.com/drugs/DB09247
    ApprovedWithdrawn

    fatalities has resulted ultimately in the agent being discontinued. … Iproclozide is an irreversible and selective hydrazine class based monoamine oxidase inhibitor (MAOI).

  10. Drug

    Liposomal prostaglandin E1

    go.drugbank.com/drugs/DB05391
    Investigational

    The liposomal formulation of PGE-1 changes the drug’s dynamics and improve its therapeutic index in ways that PGE-1 alone could not achieve. … Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent.